Przedstawiamy wybór publikacji naukowych związanych z immunoterapią IOZK. Możesz użyć filtrów, aby dokonać wyboru według typów nowotworów i metod lub wprowadzić wyszukiwane hasła.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-05-31 / J Gynecol Oncol 2016 Sep;27(5):e51https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-05-31 / J Gynecol Oncol 2016 Sep;27(5):e512016-05-31 00:00:002019-02-15 08:35:39Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-05-12 / J. Virol. 2016 06;90(11):5343-5352https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-05-12 / J. Virol. 2016 06;90(11):5343-53522016-05-12 00:00:002019-02-15 09:22:53Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-05-07 / World J. Gastroenterol. 2016 May;22(17):4275-86https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-05-07 / World J. Gastroenterol. 2016 May;22(17):4275-862016-05-07 00:00:002019-02-15 08:39:08Dendritic cell-based cancer immunotherapy for colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-05-03 / Biomedicines 2016 May;4(2)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-05-03 / Biomedicines 2016 May;4(2)2016-05-03 00:00:002016-05-03 00:00:00Cancer Vaccines in Ovarian Cancer: How Can We Improve?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg00IOZKhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svgIOZK2016-05-01 13:48:072019-02-12 13:48:48Veröffentlichung von Stefaan Van Gool MD. PhD.: Electroporation of Dendritic Cells with WT1, Survivin, and TriMix
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-05-01 / Am. J. Respir. Crit. Care Med. 2016 05;193(9):1023-31https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-05-01 / Am. J. Respir. Crit. Care Med. 2016 05;193(9):1023-312016-05-01 00:00:002020-09-07 08:01:30Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-04-29 / Front Immunol 2016;7:171https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-04-29 / Front Immunol 2016;7:1712016-04-29 00:00:002019-02-15 09:18:09Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-04-27 / J. Pharmacol. Sci. 2016 Sep;132(1):24-30https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-04-27 / J. Pharmacol. Sci. 2016 Sep;132(1):24-302016-04-27 00:00:002019-02-15 09:13:31Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-04-21 / Radiat Oncol 2016 Apr;11:60https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-04-21 / Radiat Oncol 2016 Apr;11:602016-04-21 00:00:002019-02-15 08:45:46Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-04-18 / Int J Hyperthermia 2016 06;32(4):446-54https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-04-18 / Int J Hyperthermia 2016 06;32(4):446-542016-04-18 00:00:002019-02-15 09:18:10Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-04-15 / Clin. Cancer Res. 2016 Apr;22(8):1897-906https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-04-15 / Clin. Cancer Res. 2016 Apr;22(8):1897-9062016-04-15 00:00:002019-02-15 08:45:11Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002016-04-11 / Cancer Res. 2016 06;76(12):3496-506https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2016-04-11 / Cancer Res. 2016 06;76(12):3496-5062016-04-11 00:00:002019-02-15 08:49:43T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines
Emerging immunotherapies for glioblastoma
Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research
Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
Oncolytic virotherapy for urological cancers
In Hyperthermia Increased ERK and WNT Signaling Suppress Colorectal Cancer Cell Growth
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
Dendritic cell-based cancer immunotherapy for colorectal cancer
Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Publikacja autorstwa Stefaan Van Gool MD. PhD: Elektroporacja komórek dendrytycznych z WT1, Survivin i TriMix
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of Cancer
Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy
Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy
Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms
Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro
T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines
Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer